In the United States, almost 3 million antibiotic-resistant infections occur each year1
UTILITY therapeutics is committed to combating the threat of antibiotic resistance in the US
Antibiotic resistance is one of the greatest threats to global health, including in the US.1,2 To help stem the growing resistance problem, UTILITY therapeutics is currently developing new antibiotic options for the treatment of urinary tract infections (UTIs) for the US market.
WhoWe Are
UTILITY therapeutics is led by a team of industry leaders highly experienced in the launch and commercialization of anti-infectives in the United States and abroad
UrgentUnmet Need
With antibiotic resistance compromising treatment outcomes, there is a critical need for new treatments
NewTreatment
UTILITY therapeutics has achieved several key milestones for pivmecillinam in preparation for NDA-filing
References: 1. Antibiotic resistance threats in the United States 2019. Centers for Disease Control and Prevention. December 2019. Accessed January 18, 2021. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf 2. Antibiotic resistance. World Health Organization. July 2020. Accessed January 12, 2021. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance